Zentalis Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Director and Officer Trading Arrangements
On November 16, 2023, Jan Skvarka, amember of the Company's Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 11,368 shares of the Company’s common stock until December 31, 2024.
On December 5, 2023, Diana Hausman, then amember of the Company's Board of Directors and, since January 19, 2024, the Chief Medical Officer of the Company, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 13,244 shares of the Company’s common stock until May 31, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.